• Türkçe
    • English
  • English 
    • Türkçe
    • English
  • Login
View Item 
  •   DSpace Home
  • Fakülteler
  • Sağlık Bilimleri Fakültesi
  • Hemşirelik Bölümü
  • SBF - H Makale Koleksiyonu
  • View Item
  •   DSpace Home
  • Fakülteler
  • Sağlık Bilimleri Fakültesi
  • Hemşirelik Bölümü
  • SBF - H Makale Koleksiyonu
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Retrospective analysis of patients with relapsed or refractory germ cell tumors treated with autologous hematopoietic stem cell transplantation

Thumbnail

View/Open

Makale Dosyası (228.0Kb)

Date

2018

Author

Ertürk, İsmail
Yıldız, Birol
Karadurmuş, Nuri
Tosun, Betül
Esen, Ramazan
Sürmeli, Zeki Gökhan
Başgöz, Bahadir
Özaydın, Şükrü
Hançerlioğulları, Oǧuz
Ürün, Yüksel
Erdem, Gökhan

Metadata

Show full item record

Citation

Erturk, I., Yildiz, B., Karadurmus, N., Ozaydin, S., Tosun, B., Esen, R., Surmeli, Z. G., ... Erdem, G. (January 01, 2018). Retrospective analysis of patients with relapsed or refractory germ cell tumors treated with autologous hematopoietic stem cell transplantation. Gulhane Medical Journal, 60, 4, 130-135.

Abstract

Aims: Germ cell tumors (GCT) are the most common malignancies, especially in males of 15 to 35 years of age. Tandem autologous hematopoietic stem cell transplantation (AHSCT) with carboplatin and etoposide (CE) has been performed for many years in relapsed and refractory germ cell patients, but information about AHSCT in patients with germ cell tumors is limited. We aimed to demonstrate some real-life data about patients who underwent AHSCT due to germ cell tumors. Methods: In this retrospective study, medical records of 20 patients who received CE as high-dose chemotherapy for AHSCT betweeen November 2016 and April 2018 were reviewed. Response rates at 12th month and toxicity profiles were evaluated. Results: A complete response was obtained in 15% (n=3) and a partial response was obtained in 20% (n=4) of the cases after AHSCT. The survival rate during AHSCT was calculated as 95%. When the progression-free survival time of the patients was examined, the median recurrence time was 6 months (95% CI: 5.08-6.91). The rate of recurrence was 57% in 6 months. Neutropenia, thrombocytopenia and anemia were observed during AHSCT in all patients. Conclusions: High dose chemotherapy as CE in AHSCT is a safe and effective treatment option in relapsed refractory GCT with an acceptable PFS and mortality rate. Also, highdose CE was associated with low treatment-related mortality and reasonable side effects in patients with poor prognosis.

Source

Gulhane Medical Journal60

Volume

60

Issue

4

URI

https://doi.org/10.26657/gulhane.00037
https://hdl.handle.net/20.500.11782/1194

Collections

  • SBF - H Makale Koleksiyonu [27]
  • Scopus İndeksli Yayınlar Koleksiyonu [577]
  • TR-Dizin İndeksli Yayınlar Koleksiyonu [174]



DSpace software copyright © 2002-2015  DuraSpace
Contact Us | Send Feedback
Theme by 
@mire NV
 

 




| Instruction | Guide | Contact |

DSpace@HKU

by OpenAIRE

Advanced Search

sherpa/romeo

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsTypeLanguageDepartmentCategoryPublisherAccess TypeInstitution AuthorThis CollectionBy Issue DateAuthorsTitlesSubjectsTypeLanguageDepartmentCategoryPublisherAccess TypeInstitution Author

My Account

LoginRegister

Statistics

View Google Analytics Statistics

DSpace software copyright © 2002-2015  DuraSpace
Contact Us | Send Feedback
Theme by 
@mire NV
 

 


|| Guide|| Instruction || Library || Hasan Kalyoncu Univesity || OAI-PMH ||

Hasan Kalyoncu Univesity, Gaziantep, Turkey
If you find any errors in content, please contact:

Creative Commons License
Hasan Kalyoncu Univesity Institutional Repository is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 Unported License..

DSpace@HKU: